Note from the CEO: Jennifer Hawks Bland

Summer unofficially starts this weekend and the NewYorkBIO team is planning ahead! We want to hear from you about potential in-person gatherings. Therefore, please take the survey and share your opinions with us. June is loaded with virtual events and we hope to see you in person later in the summer.

Next month, we are launching a three-part webinar series about getting back into the office with panel discussions around topics like bioscience (June 9), real estate (June 16) and government & academia (June 24). Look for those webinars in June.

Join NewYorkBIO and BioNJ on June 10th to talk about Foreign Price Controls, featuring Duane Schulthess of Vital Transformations. The impact of proposals like H.R.3 could significantly damage our ability to create new cures.

We're bringing back our Emerging Biotech Company Showcase, hosted in partnership with the New York Stock Exchange.

Please also save the date for our 2021 Annual Meeting, which will be held in Manhattan on September 27th. We're looking forward to seeing you in person again!
NewYorkBIO is proud to be partnering with the New York Stock Exchange for the third Emerging Biotech Company Showcase on June 23, 2021.

The virtual Showcase brings together New York's financial community and a group of emerging biotech companies that are developing novel therapeutics and technologies that could revolutionize patient care. This year the event will include presentations from seven up and coming European biotech companies.

Click below for more information or to register!
Virtual Breakfast Series
Tuesday, June 1, 9:00am

On Tuesday, where we will be joined by Carlo Rizzuto of Versant Ventures. Carlo has been an instrumental player in the NYC biotech ecosystem and a tremendous advocate and ambassador for biotech company creation across the region.
Sponsored By:

Carlo Rizzuto Bio
Carlo Rizzuto, Ph.D., is a Partner at Versant Ventures New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in the Northeast including Highline Therapeutics, Versant's New York City-based Discovery Engine. Prior to opening the NYC office, Carlo led negotiations to establish a strategic partnership with Astellas that led to the creation of the Anokion spinoff, Kanyos.

Carlo joined Versant from Novartis, where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising U.S. and European clients in the pharmaceutical, payor, and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup. He received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.
We're bringing together moderators and panelists for a webinar series this June, focused on bringing staff back into work places.
Got News?

Have something you'd like us to feature in the newsletter?